Sponsor Deadline
Posted: 4/18/2022

Congressionally Directed Medical Research Programs (CDMRP) -- Prostate Cancer Research Program -- Prostate Cancer Pathology Resource Network Award

The FY20 PCRP Prostate Cancer Pathology Resource Network (PCPRN) Award is intended to provide infrastructure support for the development and maintenance of a prostate cancer biorepository through a collaborative network across multiple institutions that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human prostate cancer biospecimens. A major focus of the Network must be placed on the acquisition and distribution of specimens in limited supply, such as: • Castration-resistant disease, metastatic disease, primary untreated “de novo” metastatic disease as defined by STAMPEDE or high-risk disease defined by CHAARTED, tumors of the aggressive variant phenotype • Disproportionately affected (African Americans, African-descent, Veterans, etc.) and underserved (uninsured, rural communities, etc.) populations • Active surveillance populations • Longitudinal/sequential specimens

The Network must also collect, store, and manage data derived from the distributed biospecimens, including digital images of the hematoxylin and eosin (H&E)-stained samples and blood-based germline assessments.

Applications should describe how the development of the Network biorepository will enable the prostate cancer research community to address the FY20 PCRP Overarching Challenges by utilizing Network biospecimens. Applications should propose a clearly defined mission that will guide the proposed Network’s biospecimen collection, distribution, and data collection processes.

The Network will consist of three to five Pathology Resource Sites, one of which will also serve as the Coordinating Center. These organizations will be jointly responsible for developing and maintaining the biorepository for prostate cancer research.

• Required Pre-Application Deadline: September 10, 2020
• Application Submission Deadline: September 24, 2020

Areas of Interest

The mission of the FY20 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. Within this context, the PCRP is interested in supporting research that addresses specific gaps in prostate cancer research and clinical care, with an emphasis on investing in research that will benefit patients diagnosed with lethal prostate cancer or improve quality of life for men diagnosed with this disease. All applications are required to address one or more of the following FY20 PCRP Overarching Challenges:

• Improve the quality of life for survivors of prostate cancer

• Develop treatments that improve outcomes for men with lethal prostate cancer

• Reduce lethal prostate cancer in people of African descent, Veterans, and high-risk or underserved populations

• Define the biology of lethal prostate cancer to reduce death

Eligibility Requirements

Each investigator may be named on only one FY20 PCRP PCPRN Award application as Initiating PI or Partnering PI.

PIs must be independent investigators with a faculty-level appointment (or equivalent) with access to the appropriate facilities. Eligibility is not affected by previous receipt of a PCRP PCPRN Award.

Amount Description

The PCRP plans to invest $9.6M in the Prostate Cancer Pathology Resource Network Award over a 3-year period. A total of $3.2M will be allocated from the FY20 budget to fund the first year of performance. Options will be included for continued performance in subsequent years with $3.2M expected from each of the FY21 and FY22 budgets to fund the options. The initial performance period of the award and each option period will be for 12 months. Exercise of the options for continued performance is contingent on receipt of sufficient Congressional appropriations to the PCRP in FY21 and FY22 and acceptable performance by the recipients. The anticipated direct costs budgeted for an FY20 Prostate Cancer Pathology Resource Network Award will not exceed $2.0M per year for a maximum of $6.0M for the entire 3-year performance period. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding Type